This workshop will examine CMC development of oligonucleotide therapeutics through interactive discussions. Review the key CMC concepts for oligonucleotide therapeutics and the successes and challenges for the platforms that have already progressed to product approval. Explore the use of oligonucleotides in complex and emerging modalities and assess the next generation of manufacturing platforms. Assess oligonucleotide impurities, their guidelines and how these should be controlled and addressed through interactive discussions. Delve into the regulatory expectations by phase of development and how to plan for the end goal, and understand how this can be applied to future projects